This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Gamma linolenic acid

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The value of Gamma linolenic acid in the treatment of cyclical mastalgia was believed to be more useful than in the managment of generalised premenstrual syndrome

  • in the latter, some studies show it's efficacy to be comparable only to placebo but as it has few side effects
  • a review concerning the use of gamma linolenic acid in the treatment of mastalgia concluded that this intervention was likely to be ineffective or harmful (1)

Evening primrose oil is generally available over the counter. It may be combined with vitamin B6 - up to 100 mg daily - or with over the counter mineral supplements containing potassium, as intracellular magnesium has been shown to be low in some PMS sufferers.

Note that in the UK the product licences for Epogam and Efamast (evening primrose oil preparations) have been withdrawn from October 7th 2002. This is because the Committee on Safety of Medicines stated that the therapeutic efficacy was unproven (2).

Reference:

  1. Clinical Evidence (September 2006). Breast pain.
  2. Current Problems in Pharmacovigilance (2002), 28, 12.
  3. O'Brien P (1993). Helping women with premenstrual syndrome. BMJ, 307, 1471-5.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.